Dienogest as a progestin for hormone replacement therapy

Drugs of Today

Volumn 35, Issue SUPPL. C, 1999, Pages 115-126

  Graser T ^a   Koytchev, R ^b   Romer T ^c   Georgiev, D B ^d   Muller A ^a   Hoffmann, H ^a   Oettel, M ^a  

^a BAYER PHARMA AG   (Germany)

^b Coop Clin Drug R and D ^*  (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d University Hospital of Obstetrics and Gynecology 'Maichin Dom' Bulgaria   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

DIENOGEST; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL VALERATE; KLIMODIEN; UNCLASSIFIED DRUG;

ADULT; AGED; BLEEDING TENDENCY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM ATROPHY; FEMALE; HEART PALPITATION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; INSOMNIA; LIPID METABOLISM; MAJOR CLINICAL STUDY; MASTALGIA; MULTICENTER STUDY; MYALGIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0345280086     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Grady, D., Rubin, S.M., Petitti, D.B. et al. Hormone replacement therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992, 1117: 1016-37.
2. Grady, D., Gebretsadlk, T., Kerikowske, K., Ernster, V., Petitti, D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995, 85: 304-13.
3. Hillard, T.C., Siddle, N.C., Whitehead, M.I. et al. Continuous combined conjugated equine estrogen-progestogen therapy: Effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis. Am J Obstet Gynecol 1992, 167: 1-7.
4. Düsterberg, B., Nishino, Y. Pharmacokinetic and pharmacological features of estradiol valerate. Maturitas 1982, 4: 315-24.
5. Oettel, M., Breitbarth, H., Elger, W. et al. The pharmacological profile of dienogest. Eur J Contracept Reprod Health Care 1998, 3: 1-12.
6. Gräser, T., Oettel, M. Organ targeting with the oral progestin dienogest. Drugs of Today 1996, 32 (Suppl H): 43-55.
7. Katsuki, Y., Shibutani, Y., Aoki, D., Nozawa, S. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins. Cancer 1997, 79: 169-76.
8. Römer, T. Clinical data on continuous combined HRT regimens. Gynecol Endocrinol 1998, 12 (Suppl 1): 17-24.
9. Marslew, U., Munk-Nielsen, N., Nilas, L., Riis, B.J., Christiansen, C. Bleeding pattern and climacteric symptoms during different sequential combined HRT regimens in current use. Maturitas 1994, 19: 225-37.
10. Oettel, M., Carol, W., Elger, W. et al. A 19-norprogestin without a 17α-ethinyl group. II. Dienogest from a pharmacodynamic point of view. Drugs Today 1995, 31: 517-36.
11. Obel, E.B., Munk-Jensen, N., Svenstrup, B. et al. A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment. Maturitas 1993, 16: 13-21.
12. Keller, P.J., Holtz, E., lmthurn, B. A transdermal regimen for continuous combined hormone replacement therapy in the menopause. Maturitas 1992: 15: 195-8.
13. Udoff, L., Langenberg, P., Adashi, E.Y. Combined continuous hormone replacement therapy: A critical review. Obstet Gynecol 1995, 86: 306-16.
14. Weinstein, L., Bewtra, C., Gallagher, J.C. Evaluation of a continuous combined low-dose regime of estrogen-progestin for treatment of the postmenopausal patient. Am J Obstet Gynecol 1990, 162: 1534-43.
15. Marslew, U., Overgaard, K., Riis, B.J. et al. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: Long-term ef-fects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Obstet Gynecol 1992, 79: 202-10.
16. Rauch, U., Taubert, H.D. Continuous hormone replacement therapy with estradiol valerate and chlormadinone acetate in adjustable doses. A preliminary study. Maturitas 1993, 17: 123-7.
17. Archer, D.F., Pickar, J.H., Bottiglioni, F. for the Menopause Study Group. Bleeding patterns in postmenopausal women taking combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994, 83: 686-92.
18. Marsh, M.S., Crook, D., Whitcroft, S.I.J. Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins. Obstet Gynecol 1994, 83: 19-23.
19. Ain Melk, Y. Comparison of two continuous combined estrogen/progestogen regimes in postmenopausal women: A randomized trial. Fertil Steril 1996, 66: 962-8.
20. Whitehead, M.I., Hillard, T.C., Crook, D. The role and use of progestogens. Obstet Gynecol 1990, 75: 59S-76S.
21. Staland, B. Continuous treatment with natural oestrogens and progestogens: A method to avoid endometrial stimulation. Maturitas 1992, 15: 71-8.
22. Marslew, U., Riis, B., Christiansen, C. Progestogens: Therapeutic and adverse effects in early post-menopausal women. Maturitas 1991, 13: 7-16.
23. Woodruff, D.J., Pickar, J.H. for the Menopause Study Group. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994, 170: 1213-23.